Limits...
The need for continued monitoring of antibiotic resistance patterns in clinical isolates of Staphylococcus aureus from London and Malta.

Gould SW, Cuschieri P, Rollason J, Hilton AC, Easmon S, Fielder MD - Ann. Clin. Microbiol. Antimicrob. (2010)

Bottom Line: This surveillance initiative reports on the percentage of isolates that are methicillin resistant.However, resistance to other antibiotics is not currently reported and therefore the scale of emerging resistance is currently unclear in the UK.All isolates were susceptible to linezolid, teicoplanin and vancomycin.

View Article: PubMed Central - HTML - PubMed

Affiliation: School of Life Sciences, Kingston University, Kingston-upon Thames, UK, KT1 2EE.

ABSTRACT

Background: Antibiotic resistance is an increasing problem in isolates of Staphylococcus aureus (S. aureus) worldwide. In 2001 The National Health Service in the UK introduced a mandatory bacteraemia surveillance scheme for the reporting of S. aureus and methicillin-resistant S. aureus (MRSA). This surveillance initiative reports on the percentage of isolates that are methicillin resistant. However, resistance to other antibiotics is not currently reported and therefore the scale of emerging resistance is currently unclear in the UK. In this study, multiple antibiotic resistance (MAR) profiles against fourteen antimicrobial drugs were investigated for 705 isolates of S. aureus collected from two European study sites in the UK (London) and Malta.

Results: All isolates were susceptible to linezolid, teicoplanin and vancomycin. Multiple antibiotic resistance profiles from both countries were determined, a total of forty-two and forty-five profiles were seen in the UK cohort (MRSA and MSSA respectively) and comparatively, sixty-two and fifty-two profiles were shown in the Maltese group. The largest MAR profile contained six antibiotics (penicillin G, methicillin, erythromycin, ciprofloxacin, clindamycin and clarithromycin) and was observed in the MRSA isolates in both the UK and Maltese cohorts.

Conclusion: The data presented here suggests that the monitoring of changing resistance profiles locally in maintaining treatment efficacy to resistant pathogens.

Show MeSH

Related in: MedlinePlus

A Graph illustrating the percentage of methicillin-sensitive S. aureus isolates showing resistance to a panel of antibiotics (no resistance was detected for the antibiotics: methicillin, vancomycin, linezolid and tecioplanin). MSSA Isolates were collected from LBH (n = 114) and Malta (n = 93). KEY: Black bar represents LBH MSSA isolates and white bars represent Maltese MSSA isolates.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2914044&req=5

Figure 1: A Graph illustrating the percentage of methicillin-sensitive S. aureus isolates showing resistance to a panel of antibiotics (no resistance was detected for the antibiotics: methicillin, vancomycin, linezolid and tecioplanin). MSSA Isolates were collected from LBH (n = 114) and Malta (n = 93). KEY: Black bar represents LBH MSSA isolates and white bars represent Maltese MSSA isolates.

Mentions: When comparing the results between MSSA (Figure 1) and MRSA isolates (Figure 2), it could be seen that the MRSA isolates were predominantly resistant to a greater range of antibiotics. Figure 1 shows the resistance level for individual antibiotic results for the MSSA isolates from both isolate groups (LBH and Malta). Of the fourteen antibiotics used the isolates were resistant to ten of the antibiotics and all were sensitive to methicillin; in addition to linezolid, teicoplannin and vancomycin (data not shown in graph). The highest level of resistance was recorded with the antibiotic penicillin G in both isolate cohorts and high levels of resistance (above 70%) were also seen to clarithromycin and ciprofloxacin Low levels of resistance (< 20%) were seen to the antibiotics; amikacin, chloramphenicol, rifampicin and tetracycline in both cohorts, although the level of resistance to tetracycline was slightly higher in the Maltese group (22%).


The need for continued monitoring of antibiotic resistance patterns in clinical isolates of Staphylococcus aureus from London and Malta.

Gould SW, Cuschieri P, Rollason J, Hilton AC, Easmon S, Fielder MD - Ann. Clin. Microbiol. Antimicrob. (2010)

A Graph illustrating the percentage of methicillin-sensitive S. aureus isolates showing resistance to a panel of antibiotics (no resistance was detected for the antibiotics: methicillin, vancomycin, linezolid and tecioplanin). MSSA Isolates were collected from LBH (n = 114) and Malta (n = 93). KEY: Black bar represents LBH MSSA isolates and white bars represent Maltese MSSA isolates.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2914044&req=5

Figure 1: A Graph illustrating the percentage of methicillin-sensitive S. aureus isolates showing resistance to a panel of antibiotics (no resistance was detected for the antibiotics: methicillin, vancomycin, linezolid and tecioplanin). MSSA Isolates were collected from LBH (n = 114) and Malta (n = 93). KEY: Black bar represents LBH MSSA isolates and white bars represent Maltese MSSA isolates.
Mentions: When comparing the results between MSSA (Figure 1) and MRSA isolates (Figure 2), it could be seen that the MRSA isolates were predominantly resistant to a greater range of antibiotics. Figure 1 shows the resistance level for individual antibiotic results for the MSSA isolates from both isolate groups (LBH and Malta). Of the fourteen antibiotics used the isolates were resistant to ten of the antibiotics and all were sensitive to methicillin; in addition to linezolid, teicoplannin and vancomycin (data not shown in graph). The highest level of resistance was recorded with the antibiotic penicillin G in both isolate cohorts and high levels of resistance (above 70%) were also seen to clarithromycin and ciprofloxacin Low levels of resistance (< 20%) were seen to the antibiotics; amikacin, chloramphenicol, rifampicin and tetracycline in both cohorts, although the level of resistance to tetracycline was slightly higher in the Maltese group (22%).

Bottom Line: This surveillance initiative reports on the percentage of isolates that are methicillin resistant.However, resistance to other antibiotics is not currently reported and therefore the scale of emerging resistance is currently unclear in the UK.All isolates were susceptible to linezolid, teicoplanin and vancomycin.

View Article: PubMed Central - HTML - PubMed

Affiliation: School of Life Sciences, Kingston University, Kingston-upon Thames, UK, KT1 2EE.

ABSTRACT

Background: Antibiotic resistance is an increasing problem in isolates of Staphylococcus aureus (S. aureus) worldwide. In 2001 The National Health Service in the UK introduced a mandatory bacteraemia surveillance scheme for the reporting of S. aureus and methicillin-resistant S. aureus (MRSA). This surveillance initiative reports on the percentage of isolates that are methicillin resistant. However, resistance to other antibiotics is not currently reported and therefore the scale of emerging resistance is currently unclear in the UK. In this study, multiple antibiotic resistance (MAR) profiles against fourteen antimicrobial drugs were investigated for 705 isolates of S. aureus collected from two European study sites in the UK (London) and Malta.

Results: All isolates were susceptible to linezolid, teicoplanin and vancomycin. Multiple antibiotic resistance profiles from both countries were determined, a total of forty-two and forty-five profiles were seen in the UK cohort (MRSA and MSSA respectively) and comparatively, sixty-two and fifty-two profiles were shown in the Maltese group. The largest MAR profile contained six antibiotics (penicillin G, methicillin, erythromycin, ciprofloxacin, clindamycin and clarithromycin) and was observed in the MRSA isolates in both the UK and Maltese cohorts.

Conclusion: The data presented here suggests that the monitoring of changing resistance profiles locally in maintaining treatment efficacy to resistant pathogens.

Show MeSH
Related in: MedlinePlus